Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

105.19 -0.73 (-0.69%)
Streaming Delayed Price Updated: 2:13 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Explore the top gainers and losers within the S&P500 index in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday. 
Via Chartmill
Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?
Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially... 
Via Benzinga
Topics World Trade
Exposures Tariff
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
Which S&P500 stocks are moving on Friday?
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday?
Wall Street bounced back from early losses, driven by upbeat bank earnings and cooler inflation data, while shrugging off trade war concerns. 
Via Benzinga
Topics Economy World Trade
Exposures Interest Rates Tariff
FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened
JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term. 
Via Stocktwits
Topics Animal Testing
Exposures Animal Testing Product Safety
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
These S&P500 stocks that are showing activity before the opening bell on Friday.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Via Benzinga
Tuesday's session: top gainers and losers in the S&P500 index
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
From Charles River Laboratories International, Inc.
Via Business Wire
Demystifying Charles River: Insights From 10 Analyst Reviews
Via Benzinga
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Exploring the top movers within the S&P500 index during today's session.
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Top S&P500 movers in Thursday's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Thursday?
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
3 Reasons CRL is Risky and 1 Stock to Buy Instead
Over the last six months, Charles River Laboratories’s shares have sunk to $173.44, producing a disappointing 15.7% loss while the S&P 500 was flat. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
Exposures US Equities
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
Charles River Laboratories to Present at Barclays Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Charles River Announces Agreement with Singapore General Hospital
From Charles River Laboratories International, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.